Log in

NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News

+0.09 (+1.41 %)
(As of 07/31/2020 04:00 PM ET)
Today's Range
Now: $6.48
50-Day Range
MA: $7.33
52-Week Range
Now: $6.48
Volume71,452 shs
Average Volume105,171 shs
Market Capitalization$64.02 million
P/E RatioN/A
Dividend YieldN/A
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCYX



Sales & Book Value

Annual Sales$120,000.00
Book Value$1.32 per share


Net Income$-53,710,000.00


Market Cap$64.02 million
Next Earnings Date8/5/2020 (Estimated)
+0.09 (+1.41 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SCYX stock has decreased by 16.9% and is now trading at $6.48.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of SCYNEXIS?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SCYNEXIS

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for SCYNEXIS

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.50) by $0.80.
View SCYNEXIS's earnings history

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

6 brokers have issued 12-month target prices for SCYNEXIS's shares. Their forecasts range from $35.00 to $60.00. On average, they anticipate SCYNEXIS's share price to reach $46.00 in the next twelve months. This suggests a possible upside of 609.9% from the stock's current price.
View analysts' price targets for SCYNEXIS

Has SCYNEXIS been receiving favorable news coverage?

News articles about SCYX stock have trended negative on Monday, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SCYNEXIS earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about SCYNEXIS

Are investors shorting SCYNEXIS?

SCYNEXIS saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 1,420,000 shares, a drop of 13.4% from the June 30th total of 1,640,000 shares. Based on an average trading volume of 105,200 shares, the short-interest ratio is presently 13.5 days. Currently, 15.4% of the company's shares are short sold.
View SCYNEXIS's Current Options Chain

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Matinas BioPharma (MTNB), Verastem (VSTM), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX), Trevena (TRVN) and T2 Biosystems (TTOO).

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti, CEO, Pres & Director (Age 60, Pay $937.35k)
  • Mr. Eric Francois, Chief Financial Officer (Age 45, Pay $604.91k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 55, Pay $676.13k)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 42)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a variety of institutional and retail investors. Top institutional investors include Creative Planning (2.10%). Company insiders that own SCYNEXIS stock include Gonzalez David Angulo and Marco Taglietti.
View institutional ownership trends for SCYNEXIS

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought SCYNEXIS stock in the last two years include Gonzalez David Angulo, and Marco Taglietti.
View insider buying and selling activity for SCYNEXIS

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $6.48.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $64.02 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis. SCYNEXIS employs 27 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.